海湃泰克

Hi-P Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule and biologic therapies for oncology and autoimmune diseases. The company leverages its proprietary structure-based drug design and fragment-based drug discovery platforms to target high-value pathways such as CDK4/6 and the PD-1/PD-L1 axis. Its lead candidate, HP001, is a selective CDK4/6 inhibitor currently undergoing clinical evaluation for the treatment of advanced breast cancer and other solid tumors. Hi-P Biotech aims to address unmet medical needs through the development of next-generation precision medicines with improved efficacy and safety profiles.